Michele Buck, a 20-year veteran of Hershey who assumed leadership in 2017, said she would step down from her roles as president and chief executive on June 30, 2026. The merger combines two of the ...

This was the stock's fourth consecutive day of losses.

ST Germain D J Co. Inc. raised its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 0.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.5 which represents a decrease of $-1.03 or -0.57% from the prior close of $179.53. The stock opened at $179.2 and touched a low of $176.18 ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...

AbbVie on Friday said it will post a $3.5 billion impairment charge related to last year's $8.7 billion bet on Cerevel Therapeutics following the failure of the deal's key drug candidate.

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the ...

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 2 includes Neo Performance Metals, Fannie Mae, ...

Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for AbbVie in a research note issued to investors ...